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Abstract 
 
Background: The porphyrias are heterogenous disorders caused by abnormalities in the 
chemical steps of hemesynthesis, which is a vital molecule for all of the body's organs. Porphyria 
symptoms arise mostly from effects on either the nervous system or the skin. Effects on the skin 
occur in the form of cutaneous porphyrias. Proper diagnosis is often delayed because the 
symptoms are nonspecific. Skin manifestations can include burning, blistering and scarring of 
sun-exposed areas. 
 
Objectives: To date there have been no reports on the molecular analysis of Porphyria in the 
Palestinian population. Therefore, the aim of this study was to confirm the clinical diagnosis of 
porphyria by biochemical and genetic tests in suspected patients from Hebron district and to 
determine the gene that cause the phenotype and clinical symptoms of cutaneous porphyria. 
 
Method: 40 patients from Tafouh /Hebron city–who have been clinically diagnosed with 
cutaneous porphyria were recruited, Biochemical and genetic studies were performed using 
different molecular techniques like cloning, Polymerase chain reaction (PCR), Restriction 
fragment length polymorphism (RFLP), sequencing and next generation sequencing to 
investigate the causative mutations at DNA and mRNA levels. 
 
Results: According to this study, the biochemical test that involves checking the total porphyrin 
and porphyrin precursor levels in urine give normal results for all the tested patients. Continually 
none of the Uroporphyrinogen decarboxylase (URODNC_000001.11), uroporphyrinogen III 
synthase (UROSNC_000010.11), and Ferrochelatase (FECHNC_000018.10) genes give any 
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significant mutation using PCR-based techniques, Restriction fragment length polymorphism 
(RFLP), Sanger and Next generation sequencing. 
In conclusion, deeper molecular tests is needed as doing exome/whole genome sequencing , 
epigentic modification analysis for these patients or invistigating a novel mutation that causes a 
new genetic disorder.  
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Chapter 1 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 Introduction 
1.1 Historical background 
The porphyrias are heterogeneous disorders arising from predominantly inherited catalytic 
deficiencies of specific enzymes along the heme biosynthetic pathway (Frank et al., 1998; 
Wiederholt et al., 2006).The history of the porphyria started with the first allusion to the pigment 
so called Porphyrins by Scherer et al (1841). Hoppe-Seyler in (1871) explained the disease 
biochemically, he clarified that the iron free hematin described by Mulder previously (1844) was 
mixture of two substances, named hematoporphyrin which resulted from an error in the 
biosynthesis of hemoglobin. Gunther in (1911) defined this entity as haematoporphyria congenita 
and was the first who recognize it as an inborn error of metabolism(Desnick and Astrin, 2002; 
McCall-Anderson, 1898; Ramanujam and Anderson, 2015).The terms hamatoporphyrin which 
named by Hoppe-Seyler resulting from the Greek (Porphyries)meaning purple, after his 
nomenclature the term PORPHYRIN was subsequently used by others. (Ramanujam and 
Anderson, 2015). 
 
1.2 Biochemistry of Porphyria 
 
1.2.1 Heme Biosynthesis (Porphyrin  Biosynthesis) 
 
The sequence of the biosynthetic pathway was excellently established by the middle of 1950s 
after many trials started by Sheminand Neubergerm who comprehended the primary description 
of how glysine was merged into heme (Goldberg et al., 2013). 
Heme like chlorophyll are porphyrin, which considered as a primordial molecule and is one of 
the fundamental pigments of life, that play a critical role in various biological processes. 
Moreover, it acts as an essential cofactor for cytochromes, oxidases, peroxidases, catalases, 
hemoglobin and myoglobin in organisms (Tzou et al., 2014). 
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Its  biosynthesis takes place mainly in the erythroblastic system (80%) and hepatocytes (15%) as 
well as in other tissues (5%), and it is formed by the condensation of 5-aminolevulinic acid 
(ALA) from glycine (Gly) and succinyl-CoA, catalyzed by δ-aminolevulinic acid synthase 
(ALAS). Two molecules of ALA are then condensed by ALA dehydratase (ALAD) yielding 
monopyrrole porphobilinogen (PBG). The enzyme hydroxymethylbilane synthase (HMBS, 
previously called PBG deaminase or PBGD ) catalyzes the head-to-tail synthesis of four PBG 
molecules to form the linear tetrapyrrole HMB and discharges four molecules of ammonium then 
converted to uroporphyrinogen III in the presence of uroporphyrinogenIII synthase (UROIIIS) or 
spontaneously to uroporphyrinogen I. The uroporphyrinogen III undergoes decarboxylation by 
the cytoplasmic enzyme, uroporphyrinogen decarboxylase (UROD), to form coproporphyrinogen 
(Copro’gen) III and in the next step Coproporphyrinogen III oxidase (CPOX) then catalyses 
oxidative decarboxylation of coproporphyrinogen III to protoporphyrinogen IX. The next series 
of sequential decarboxylation reactions are carried out by a single cytosolic enzyme, called 
protoporphyrinogen oxidase (PPOX), to form protoporphyrin ;IX (PP). The final step of heme 
biosynthesis, catalyzed by the enzyme, ferrochelatase (FECH, also known as heme synthase), is 
the insertion of ferrous iron into PP to produce heme (Besur et al., 2014; Dailey and Meissner, 
2013; Schubert et al., 2009; Szlendak et al., 2016). Step by step reactions are shown in Figure 1.1 
 
 
Figure1.1:The heme biosynthetic pathway showing intermediates, enzymes and types of porphyria associated with 
each enzyme. 
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1.2.2 Heme Biosynthesis Pathway Regulation 
Regulation of the genes encoding the eight enzymes of the heme biosynthesis pathway can occur 
at the transcriptional, translational and post-translational levels. (Tzou et al., 2014). 
The predominantly regulation occurs in the first step which is catalyzed by ALAS, the rate-
limiting enzyme in the heme biosynthesis pathway, and regulated in several ways. Primarily, the 
enzyme is subject to inhibition by heme, although this may be of only minor significance in 
mammalian tissues. Furthermore, heme regulates at the transcriptional level in the liver cell 
where it seems to conjoin with an apo-repressorprotein(Jordan and Dailey, 1990). 
A housekeeping promoter operated in all tissue types exists in ALAS1, PBGS, PBGD, and 
UROS. However, for ALAS2, PBGS, PBGD and UROS, erythroidspecific promoters drive gene 
expression. More notably, the alternative promoters found in PBGS, PBGD and UROS are 
locatedin intron 1, and an alternative splicing event is mandatory for the transcript generated 
from the housekeeping promoters and erythroid-specific promoters, consequently the presence of 
two genes, one encoding the liver mitochondrial enzyme and the other the erythroid enzyme, are 
regulated by altered tissue-specific mechanisms(Besur et al., 2014; Jordan and Dailey, 1990; 
Tzou et al., 2014). 
 
1.3 Classification of Porphyria 
Porphyria disorders are broadly classified as acute/inducible porphyrias or chronic cutaneous 
porphyriasas shown inTable1. (Karim et al., 2015; Thapar and Bonkovsky, 2008). Moreover, the 
classification is based on the main site of heme precursors production either in the  liver (hepatic) 
or in bone marrow (erythropoietic). On the other hand, the classification can be according to the 
cardinal clinical features (either neuro-visceral or cutaneous) and/or by the enzyme defect (Besur 
et al., 2014; James and Hift, 2000; Magnus, 1968). Therefore, it is imperative to note that there is 
no one single simple classification of porphyrias, and the clinical features of various forms may 
be similar. 
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Table 1.1 : Classification and Major Features of Human Porphyrias(Thapar and Bonkovsky, 2008). 
 
†autosomal recessive inheritance has been described. 
 
1.3.1 The hepatic porphyria 
1.3.1.1 Clinical manifestations 
Hepatic porphyrias comprise hereditary coproporphyria (HCP), variegate porphyria (VP), acute 
intermittent porphyria (AIP), aminolevulinic acid dehydratase deficiency porphyria (ADP), and 
porphyria cutaneatarda  (PCT). Of these, ADP and AIP are categorized as acute porphyria but 
PCT as cutaneous, while VP and HCP presenting with both acute and cutaneous clinical 
manifestations (Arora et al., 2016; James and Hift, 2000). 
In the case of the acute (neurologic) porphyrias, the origin of symptoms appears to be due to over 
production of a neurotoxic precursor (Bissell and Wang, 2015) , so the major manifestations of 
these disorders are acute neurologic attacks, which typically occur after puberty. Constipation, 
abdominal distension nausea, vomiting, tachycardia, hypertension, mental symptoms, extremity, 
neck, or chest pain, headache, muscle weakness, sensory loss, tremors, sweating, dysuria, and 
bladder distention are common (Balwani and Desnick, 2012; Szlendak et al., 2016). 
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Three of the acute hepatic porphyrias (acute intermittent porphyria (AIP), hereditary 
coproporphyria (HCP), and variegate porphyria (VP)) are autosomal dominant disorders, 
affecting males and females equally. A fourth type, delta aminolevulinic aciduria (ALAD), is 
autosomal recessive and very rare (Bissell and Wang, 2015). 
1.3.1.2 Pathogenesis of Acute Attacks 
The pathogenetic mechanisms which cause the neurological dysfunction have stayed poorly 
understood. Obviously, stimulation of the acute attacks is prompted by severe fasting or dieting, 
alcohol, certain drugs (mainly barbiturates, hydantoins, rifampin, sulfonamides and endogenous 
steroid hormones, estrogen and progesterone), chemical compounds particularly paint, varnish, 
organic solvents, pesticides and other intercurrent illnesses or stress. So it is essential to 
recognize at-risk relatives and to offer asymptomatic heterozygote counseling to evade those 
factors, and other precipitants of the acute attacks (Balwani and Desnick, 2012; Besur et al., 
2014;Yeung Laiwah et al., 1987). 
 
1.3.2 Erythropoietic porphyrias 
Porphyrins in red cells can cause photosensitive cell lysis, resulting in haemolytic anaemia. The 
two homozygous erythropoietic porphyrias, congenital erythropoietic porphyria (CEP) and 
hepatoerythropoietic porphyria (HEP), are accompanied by haemolytic anaemia of varying 
degrees. In contrast, erythropoietic protoporphyria (EPP), a heterozygous disease, infrequently 
associated with haemolytic anaemia. The effect of life-long anaemia in CEP or HEP may lead to 
compensatory increase of erythroid marrow, which may result in pathological fractures, vertebral 
compression or collapse, and shortness of stature. The haemolysis is also associated with varying 
degrees of splenomegaly and the production of pigment-laden gallstones (Sassa, 2006) . 
 
1.3.2.1 Congenital Erythropoietic Porphyria (CEP) 
Congenital erythropoietic porphyria (CEP; OMIM: 263700), also known as Gunther's disease, is 
a very rare with prevalence estimates to be less than one of million is affected with this disease 
(Ramanujam and Anderson, 2015; Thadani et al., 2000). . It is inherited as an autosomal 
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recessive trait in which the activity of uroporphyrinogen III cosynthase (URO-synthase), the 
fourth enzyme in heme biosynthesis is severely reduced (Mathews et al., 2001; Wiederholt et al., 
2006). 
The ∼34-kb human URO-synthase gene was consigned to the narrow chromosomal region 
10q25.3--- q26.3 and organized in 10 exons and 2 mRNA transcripts generated by alternative 
splicing, directed from unique housekeeping and erythroid-specific promoters, as well the 
expression arrays revealed that the housekeeping transcript was present in all tissues, while the 
erythroid transcript was only in erythropoietic tissues(Aizencang et al., 2000a; Aizencang et al., 
2000b; Desnick and Astrin, 2002).Many mutations that cause CEP have been reported in the 
URO-synthase gene like missense and nonsense mutations, large and small deletions and 
insertions. In addition to that there are an altered splicing, frameshift, intronic branch poin 
mutations and erythroid-specific promoter mutations.(Desnick and Astrin, 2002; Fontanellas et 
al., 1996; Ged et al., 2004a; Xu et al., 1995; Zlotogora, 1997; Zlotogora, 2002). 
The reduced URO-synthase activity leads to accumulation of uroporphyrin in other tissues that 
gives rise to skin photosensitivity, ulcers, erosions, erythrodontia, osteodystrophia, combining 
osteolysis and osteoporosis. Secondary infections of cutaneous lesions may induce to scarring, 
deformities, and disfigurement of the light-exposed parts of the body particularly on the 
forehead, upper cheeks, hands, ears, nose and eyelids. The severe photosensitivity can be noticed 
in infancy or childhood (Di Pierro et al., 2015; Sassa and Kappas, 2000; Thadani et al., 2000). 
Few factors are responsible for the phenotypic inconsistency including the amount of the 
remaining URO-synthase activity, the haemolysis degree, consequent stimulation of 
erythropoiesis, and the exposure to ultraviolet light. Consequently, as in other porphyrias, a 
relationship between environmental factors and the deficient enzyme activity is essential in the 
clinical expression of the disease (Desnick and Astrin, 2002; Sassa and Kappas, 2000; Thadani et 
al., 2000). 
Typical and severe CEP symptoms encountered within a Palestinian family in France due to 
novel mutation (S47P).Four siblings were shown to have the disease (Ged et al., 2004b). 
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1.3.3 Cutaneus Hepatic Porphyria 
1.3.3.1 Porphyria CutaneaTarda (PCT) 
Porphyria cutanea tarda (PCT; OMIM: 176100) is a hepato cutaneous porphyria triggered by a 
deficiency in uroporphyrinogen decarboxylase (UROD), this cytosolic protein is the fifth enzyme 
in the hemesynthesis pathway, and can be classified into severaltypes, familial PCT (fPCT) and 
sporadic PCT (sPCT) which being the most common. PCT is found in a sporadic form (sPCT) 
with no evident mutation and an inherited form, familial PCT (fPCT) with mutation in the gene 
UROD. The disease fPCT is inherited in an autosomal dominant way with reduced penetrance 
described by low UROD activity in all cells, the reduced or incomplete penetrance means that 
not all individual carrying a mutation in UROD-gene will show the clinical phenotype(Bulaj et 
al., 2000; Christiansen et al., 2016; Elder, 1998; Poblete‐Gutiérrez et al., 2004). 
The level of UROD activity in erythrocytes has conventionally been used to discriminate 
between fPCT and sPCT, because sPCT shows reduced UROD activity only in the liver while 
fPCT is characterized by low UROD activity in all cells(Aarsand et al., 2009) 
The human UROD gene has been mapped to the short arm of chromosome 1 (1p34). The gene is 
~3.4 kb and contains a single promoter and 10 exons. Its mRNA has 1.2 kb and encodes a 367 
amino acid poly peptide with a molecular weight of approximately 41 kDa (Dubart et al., 1986).  
 
Approximately 70 different mutations have been identified in UROD that are associated with 
 F-PCT or the homozygous variant of PCT that named hepato erythropoietic porphyria [HEP]. 
PCT, perhaps the most common of all the porphyrias worldwide. Estimates of prevalence have 
fluctuated from one in 5000 to 25000 or one people in 10,000 (Aarsand et al., 2009; Ramanujam 
and Anderson, 2015). 
 
PCT is characterized clinically by a photosensitive dermatosis associated with skin fragility 
which is considered a specific feature and blistering that usually presents with vesiculobullous 
eruptions on the hands and face, a minimal trauma is followed by superficial erosion soon 
covered by a crust, Hypertrichosis is often seen on the upper cheeks, ears and arms. Increased 
pigmentation of sun-exposed areas is common and signs of liver damage.  
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Porphyria cutanea tarda is associated with an increased incidence of the haemochromatosis gene 
mutation. Treatments for PCT include withdrawal of aggravating factors, phlebotomy and oral 
antimalarial medications. 
The rare homozygous form of f-PCT is referred to as hepato erythropoietic porphyria (HEP), and 
is characterized by the onset in early childhood with more severe clinical features than PCT, 
resembling that of congenital erythropoietic porphyria(Gómez-Abecia et al., 2013). 
 
1.1.1.1.1Hepatoerythropoietic Porphyria 
Hepatoerythropoietic porphyria (HEP) is a severe form of cutaneous porphyria that manifest 
early in infancy, with similar frequency in females and males, UROD activity in HEP is 
exceedingly low, leading to the assumption that HEP maybe a homozygous form of PCT. The 
disorder is caused by homozygosity or compound heterozygosity for mutations of the 
uroporphyrinogen decarboxylase (URO-D) gene (Moran-Jimenez et al., 1996; Phillips et al., 
2007).  
HEP is characterized clinically by severe photosensitivity, skin fragility (bullae, erosions, and 
scarring) in sun-exposed areas, facial hypertrichosis, chronic anemia, polyarticular arthritis with 
high levels of circulating porphyrins, there may be a red/brown discoloration of teeth due to the 
deposition of porphyrins in the enamal layer of the developing tooth (erythrodontia)and pink-to-
red-colored urine. HEP commonly presents in early childhood in contrast to PCT, which is 
mostly revealed in adults ,increased severity causing disfigurement(Cantatore-Francis et al., 
2010; Meguro et al., 1994). 
The disease arises worldwide and is inherited as an autosomal recessive trait either gene deletion, 
defective transcription, abnormal processing of the mRNA, unstable or untranslatable mRNA or 
that the protein coded for by the mutant gene is unstable in vivo that causing markedly lacking, 
but not absent, activity of the heme biosynthetic enzyme, uroporphyrinogen decarboxylase 
(UROD)(De Verneuil et al., 1986). 
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1.3.3.2. Erythropoietic protoporphyria (EPP) 
Erythropoietic protoporphyria (EPP; OMIM: 177000) is an inherited disorder of heme 
biosynthesis that outcomes from a partial deficiency of ferrochelatase (encoded by the FECH 
gene), the last enzyme in the heme biosynthesis pathway. The human FECH gene is located on 
chromosome18q21.3 with 11 exons and 10 introns that catalyse the insertion of iron into 
protoporphyrin ring to generate the last product, haem (Balwani et al., 2014; Parera et al., 2009). 
EPP was first designated by Magnus in 1961, and was described by excessive production 
and consequent accumulation of metal-free protoporphyrin (PP) in erythrocytes, plasma, skin, 
and liver(Gouya et al., 2006; Lane et al., 2016a).  
 
The main site of protoporphyrin overproduction is localized to the bone marrow, where 
erythrocytes are produced .Protoporphyrin, unlike other porphyrins, is lipophilic molecule and 
thus detached from the body only through hepatic excretion into bile or feces. In contrast to the 
other forms of cutaneous porphyria, the urinary porphyrins are usually normal (Thapar and 
Bonkovsky, 2008). 
Clinically, EPP is described by photosensitivity that arises in early childhood and includes 
burning, swelling, itching, and painful erythema in sun-exposed areas. Chronic liver disease is an 
important complication in a minority of EPP patients, and in some cases liver transplantation has 
been performed(Balwani et al., 2014; Parera et al., 2009). 
Repeated photosensitivity episodes cause alteration in skin appearance with everlasting changes, 
such as skin thickening with a waxy or leathery appearance, lichenification, grooving around the 
lips and areas of hyperkeratosis. These lesions are usually located on the dorsa of the hands and 
face, as these skin areas are usually exposed. 
The condition is inherited as an autosomal dominant disorder, but recessive inheritance with two 
mutated FECH alleles has also been well-defined.  
EPP is the third most common porphyria, with a general estimated incidence of two to five in 
1,000,000; it is the most common porphyria in children. On the other hand, the autosomal 
dominant state has been indicated worldwide with prevalence between 1:75,000 and 1:200,000, 
it looks that males and females are likewise affected, furthermore the prevalence of autosomal 
recessive EPP has not been recognized but few studies in a small number of families propose that 
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up to 20% of patients may have autosomal recessive disease (Lane et al., 2016b; Lecha et al., 
2009; Whatley et al., 2004).   
 
1.4 Diagnosis of  Porphyria  
The diagnosis of CEP, PCT and HEP is established in probands by identification of raised up 
porphyrins in the urine (≈20 times of the usual upper limit) mainly uroporphyrin and 
heptacarboxylporphyrin besides to the increased erythrocyte zinc protoporphyrin level. On the 
other hand, the diagnosis of EPP is established by detection of markedly increased free 
erythrocyte protoporphyrin since the urinary porphyrins are usually normal. Even though each 
type of porphyria has a typical porphyrin excretion pattern, those excretion profiles of urinary 
and faecal porphyrins are sensitive but unspecific in differentiating porphyrias. Thus, the 
identification of pathogenic variants in UROS, UROD and FECH genes by molecular genetic 
testing approve the diagnosis(Balwani and Desnick, 2012; Danton and Lim, 2006; Meguro et al., 
1994;Ramanujam and Anderson, 2015).   
Table 1.2:  Accumulation and excretion patterns of heme precursors and intermediates in body fluids 
 
http://www.pinsdaddy.com/signs-and-symptoms-of-porphyria 
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1.5 Research significance  
Porphyria is a group of at least eight metabolic disorders resulting from a malfunction in one 
of the eight steps in the body's synthesis of heme. In Palestine, several pateints were 
clinically diagnosed by inherited porphyria, all of them badly suffered from the clinical PCT 
symptoms. 
This is the first genetic study on the Palestinian population focusing on the porphyria. The 
outcome of this research will contribute in identification of clinically asymptomatic 
heterozygous carriers within families. The study will enable correct and early diagnosis, 
which is required to develop a management plan that is appropriate to improve prenatal 
diagnosis for Porphyria families. It will provide them with a better genetic counseling 
correspondingly the outcome of this study and other future studies will help in drawing a 
genetics map for this disease in Palestine, which can be used in better advising and 
management of the Palestinian patients. 
The objectives of this research are: 
1. To confirm clinical diagnosis of porphyria by biochemical test and genetic study. 
2. To determine the genes that cause the phenotypic characterization and symptoms. 
3. To determine the molecular nature of the mutations that are correlated with the      
phenotypes in Palestinian patients and establish a diagnostic marker for mutation 
detection that is correlated with disease symptoms. 
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Chapter 2 
ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 Material and Methods 
2.1 Working Plan 
In this study we planned to reveal the molecular nature of the genetic mutations that is 
suspected to be the cause of cutaneous porphyria in suspected Palestinian patients who 
clinically diagnosed by porphyria based on their symptoms and   family history. 
Molecular genetic  approaches that include single-gene or a multi-gene testing, and more 
comprehensive genomic testing like deep sequencing were used. In parallel, the identification 
of the unique pattern of overproduction of porphyrin   and  porphyrin precursors by 
biochemical test was performed using 24 hrs Urine collection / Porphyrin test. 
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Figure 2.1: Flow chart demonstrates the working plan for our study 
The porphyria types divided according to the symptoms and inheritance pattern, we followed the 
recessive pattern according to families’ history of cutaneous symptoms, and the genetic studies 
for three genes were performed in parallel with biochemical test. 
 
 
2.2 Patients and Controls 
The study included all suspected Porphyria patients in Tafouh village- Hebron District. The 
population of the village around 10,597 persons in    2007[Palestinian Central Bureau of 
Statistics, 9002, General Population, Housing and Establishment Census, Ramallah, Palestine]. 
Forty related and unrelated Porphyria suspected patients, family members and three normal 
controls were included, Twenty two patients out of forty  were enrolled in the study .The 
diagnosis of Porphyria was established according to the clinical presentation and followed by 
biochemical and genetic tests to confirm and specify the compatable disorder. 
 
2.3Ethical issues 
Patients and their families were informed about the aim of the study. The study was done in 
collaboration with the Palestinian Ministry of Health in Ramallah. The patients were clinically 
diagnosed as porphyria suspected patients based on the consensus of ministry of health 
dermatologist. All patients were invited to the primary health Clinic in order to participate in the 
study. Participation was on a voluntary base. 
An agreement was assigned between Al-Quds University (Al-Quds Nutrition and Health 
Research Institute) and Medicare lab-Hebron branch to transfer the urine samples to Biolab in 
Jordan.  One-liter light protected plastic containers were provided to the patients for urine 
collection, this step was approved correspondingly by the Ministry of health and Tafouh 
municipality. 
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2.4 Logistics of Sample Collection 
2.4.1 Samples for Genetic analysis 
 Peripheral blood (5 ml) was taken from each patient. The drawn blood was placed in an 
ethylenediaminetetraacetic acid (EDTA) tube. The contents were mixed by inverting the tubes 5-
8 times without shaking. Blood samples in EDTA tubes for DNA and RNA extraction were 
transferred immediately to Al-Quds Nutrition and Health Research Institute (ANHARI) Lab. A 
buffy coat separated and saved at 4-8 C
o
at   (ANAHRI) refrigerator until further analysis. 
Our study included DNA and RNA investigation to cover all types of possible mutations 
including missense and nonsense mutations, large and small deletions and insertions. In addition 
to study any altered splicing that cause exon skipping, frame shift, intronic branch point 
mutations, etc. 
 
2.4.2 Samples for Biochemical Studies  
Accurate diagnosis of clinically overt porphyria requires identification of the unique pattern of 
overproduction of total porphyrin and the following precursors (Uroporphyrin Heptacarboxy 
porphyrin, Hexacarboxy porphyrin, Pentacarboxy porphyrin, CoproporphyrinI Coproporphyrin 
II).Therefore, fourteen patients participated in the biochemical test, (24-Hour) urine sample 
collection for Porphyrins fractions analysis was requested through Medicare lab- Hebron branch 
to transfer the samples to Biolab in Jordan. The special container was provided to the patients, 
moreover they were provided with the instruction how to collect the sample and to store it, which 
were described at the Medicare lab website guidelines [http://medicare.ps/en/test/porphyrins-
fractions-urine].The collected samples were protected from light and kept refrigerated during 
collection. 
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2.4.3 Preparing DNA samples 
1. Genomic DNA was extracted from blood Buffy Coat using a QIA amp DNA blood Mini kit 
according to the manufacturer’s protocol. Control DNA was extracted from healthy people 
with no symptoms of porphyria and/or family history. 
2.  The concentration of extracted DNA was measured using Nano Drop ND. 
3. The extracted DNA was stored at -20 C for mutation analysis. 
 
2.5 Molecular DNA analysis 
The DNA analysis was performed for three genes (UROD), uroporphyrinogen III synthase 
(UROS), and Ferrochelatase (FECH) according to the recessive pattern of inheritance in 
those genes to find the compatible mutation for the cutaneous symptoms.  
 
2.5.1 UROD gene analysis on DNA and RNA levels 
DNA analysis was done using the followed methods: cloning the whole gene (3.6Kb) 
including the exons and introns followed with Sanger sequencing and next generation 
sequencing. RNA analysis was done by production of cDNA from the extracted RNA 
followed by amplification of the spliced transcript. 
 
2.5.1.1 Cloning UROD gene in a plasmid vector and Sanger sequencing (UROD gene 
amplification) 
The molecular analysis of DNA and mutations screening have been made possible by the 
cloning of DNA  since  limited volume of blood sample was collected and several rounds of   
amplifications were needed to detect the suspected mutations. 
 
2.5.1.2 PCR Master Mix set up and Condition of the PCR reaction 
The UROD gene (3.6 Kb) for three patients from different families was amplified using Uro-DU 
forward and Uro-DL reverse newly designed primers (table 2.2),in a final concentration of 
0.4µM. The LongAmp Hot Start Taq X2 Master Mix (M0533S, Lot:0061309) was used. PCR 
preparations were done as described in )table 2.1(. The PCR reaction conditions were started 
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with initial denaturation for 30 second at 94ºC. Amplification was achieved in 36 cycles started 
from denaturation step for 20 seconds at 94ºC followed by  30 seconds at 55ºC  for annealing and  
3 min at 72ºC for extension, respectively. An additional extension step was performed for 10 
minutes at 72 ºC.  The reaction was then cooled down to 4ºC and either stored at -20 ºC or used 
directly for analysis. The reaction was carried out in special PCR tubes (0.2 ml Axygen Inc., 
USA) using Biometra thermocycler (TProfessional basic gradient). 
 
Table 2.1: Setting up PCR reaction using LongAmp Hot Start Taq 2X Master Mix  
Component  Volume for one reaction (μL) Final 
Concentration 
2X LongAmp Hot Start Taq 25 1X 
Uro-DU Forward primer (10 μM) 2 0.4μM 
Uro-DLReverse primer (10 μM) 2 0.4μM 
Free nuclease water ( up to 50 μL) 16  
DNA template  5 ≈ 100 ng/μL 
 
2.5.1.3 Detection and Purification of PCR product 
The amplified gene of the expected size of (3.6 Kb) was separated by agarose gel 
electrophoresis. Agrose gel (1 %) (Seakem LE Agarose, Lonza cat#: 50004) was prepared in X1 
TAE (Tris Acetate-EDTA buffer)(X10 TAE = 400nM Tris-HCL, pH 8.3; 200mM Na-Acetate; 
20 mM EDTA). The agarose was boiled until it was well melted; ethidium bromide (0.5 mg/ml) 
was added when agarose suspension had cooled down, carefully mixed, poured into the agarose 
gel casting system (Bio-Rad, Consort EV245) and a comb was added to generate sample wells. 
PCR product (50ul) was mixed with 4 μl of the X6 DNA loading dye (Thermoscientific) and 
loaded into one gel well along with 4 µl of 1 kb molecular weight ladder marker, (Thermo 
scientific gene ruler 1 kb Plus DNA Ladder. The PCR products (10 ul) were visualized under UV 
light.  A digital image of the gel was taken using a gel documentation system (Bio imaging 
system,Minilumi). The PCR product rest was kept frozen for Purification and preparing for 
cloning. 
The Wizard® SV Gel and PCR Clean-Up System (Promega, Part#:9FB072) was used forPCR 
product purification. The steps were accomplished according to the manufacturer's instructions. 
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The purified samples were eluted in 50 μL of Nuclease-Free water and stored at -20 °C until 
further analysis. 
 
2.5.1.4 Blunting, ligation reaction and cloning of UROD gene 
The blunting step is essential for the PCR product since Taq polymerase product is an overhang 
product and thus further plasmid was prepared as blunt end according to the manufacturer’s 
instructions (Thermo Scientific Clone JET PCR Cloning Kit, #K1231).The process of ligation 
was completed on ice by adding 1.4μL from pJET1.2/blunt Cloning Vector (50ng/ μL) and 1.4 
μL from T4 DNA Ligase to the blunting reaction mixture. Schematic representation of the 
pJET1.2/blunt Cloning Vector was shown in figure 2.1 
 
 
Figure 2.2: Map and features of pJET1.2/Blunt Cloning Vector 
 
 
2.5.1.5 Competent cells preparation (DH5α) 
Competent cells are -ready to use- bacterial cells that possess more easily altered cell walls by 
which foreign DNA can be passed through easily. Most types of cells cannot take up DNA 
efficiently unless they have been exposed to special chemical or electrical treatments to make 
them competent.  The standard method for making the bacteria permeable to DNA involves 
treatment with calcium ions. Brief exposure of cells to an electric field also allows the bacteria to 
take up DNA and this process is called as electroporation. The competency can be obtained by 
creating pores in bacterial cells by suspending them in a solution containing high concentration 
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of calciumi.eCaCl2. DNA can be forced into the host cell (DH5αE. coli) by heat shock treatment 
at 42
o
C for the process of transformation. The protocol was followed as mentioned below: 
Day1: 
1.A portion from the top of the frozen glycerol of DH5αE. coli stock was scraped off by sterile 
disposal inoculating loop and inserted into 2ml LB broth (LB broth was prepared by adding 10 g 
from Trypton,5 g from Yeast Extract and 10 g NaCl in 1 Litre of distilled water, the obtained 
broth media was autoclaved at 121°C (249 °F) for around 20 minutes). 
2. DH5α E. coli stock was retained back to -80C immediately. 
3. The tube was incubated with shaking at 37 °C for 16-20 hours. 
 Day2: 
4. 1ml culture broth was added to 49 ml of LB medium (1:50), to achieve bacterial log phase. 
Then it was incubated in a water bath at 37°C with shaking for 2.5 hours. 
5. The turbidity was observed by eye and measured by spectrophotometer as it reach0.4OD at 
wavelength 550A. 
6.   The flask was placed in an ice for 10 minutes [After this point the cells should be never 
warmed]. 
7. The culture was transferred into pre-chilled 50ml falcon tube. 
8.  The centrifugation process was performed at 4000 rpm for 15 minutes at 4°C 
9. The medium was removed, the cell pellet was washed with cold 50mM CaCl2 and finally re-
suspended by gentle flicking in a final volume of 5ml  of ice cold  CaCl2 (50mM). 
10. The tube was incubated on ice for 30 minutes then centrifuged at 2500 rpm for 10 minutes at 
4°C 
11. The medium was removed, the cell pellet was re-suspended in a final volume of 5ml ice cold 
   CaCl2 50mM -by gentle flicking-including 7% DMSO.  0.5 ml were prepared in aliquots and 
stored in -80 °C for transformation. 
 
2.5.1.6 Transformation 
As shown in figure 2.2 the prepared competent cells (200 µl) were thawed directly on ice, then   
2 µl of the ligation mixture was added. The reaction was incubated for 30 minutes on ice, 
incubated at 42°C for 1 min, transferred immediately on ice, and then 800 µl of LB was added to 
the tube and incubated for 1 hour at 37°C with 200 rpm shaking. 
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Figure 2.3: Preparation of competent cells by CaCl2 treatment and transformation 
 
2.5.1.7 Positive selection of transformed DH5α cells  
The vector contains lethal gene eco47IR enables positive selection of recombinant plasmid that 
is disrupted by ligation of a DNA insert into the cloning site. As a result, only bacterial cells with 
recombinant plasmids are able to form colonies. Re-circularized pJET1.2/blunt vector molecules 
lacking an insert express a lethal gene, which kills the host E. coli cell after transformation and 
keep only positive selection of recombinant plasmid. 
To confirm the transformation process around 60μl of the transformed cells were plated on LB 
Agar contains Ampicillin for positive selection in Petri dishes (E.coli Fast Media, Fermentas Life 
Science Company). The plate was incubated at 37°C for 12-14 hours, at least 10 colonies after 
that was inoculated in 1-5 mL of LB medium supplemented with the appropriate selection 
antibiotic (Ampicillin). Then they were incubated overnight at 37°C while shaking at 200-250 
rpm. 
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This step was prepared to enhance the growth rate. The turbidity was checked, then 500 µl 
from each suspension was taken, subsequently boiled at 95°C for 10 minutes, centrifugation 
process was done to get a DNA pellet which re-suspended in 70 µl free nuclease water. 
PCR master mix and amplification reaction was done as mentioned previously in section 
2.4.2.1but the Primers for UROD gene were replaced by the plasmid pJET1.2 forward and 
reverse sequencing primers, (10 µM)(Thermo Scientific Clone JET PCR Cloning Kit). 
2.5.1.8 Plasmid extraction for DNA preparation from clones  
This part was completed by using PureYield™ Plasmid Mini prep Zxcvbnm System, Promega, 
Part# 9FB093.The protocol was followed according to the leaflet by preparing lysate, washing 
and elution step then the eluted plasmid DNA was stored at –20°C. The required plasmid 
concentration was needed to perform sequencing step was ranged between (100-300 ng/μL). 
 
2.5.1.9 UROD gene and Sanger sequencing 
The screening for  genetic changes were performed for full gene and for internal sequences 
that we designed as explained below in the table 2.2 and figure 2.3 to detect any homozygous 
mutation or compound heterozygotes that cause PCT or HEP a recessive form of PCT. In 
addition, primers were designed with consideration of overlaps to achieve complete sequence 
of the gene (see figure 2.3 below). 
Table 2.2:Primer sets that used for UROD gene amplification and sequencing 
Primer code Sequence 5’---3’ Reference 
pJET 1.2 F 5'-CGACTCACTATAGGGAGAGCGGC-3' Thermo Scientific CloneJET PCR 
Cloning Kit ,#K1231 
Uro-DU 5'-TATGGACCTGGCTGGATAAGACTGTTGGT-3' Mendez,M.,Sorkin1998 
UroDR3 5'-CGGGAGTGTAGTCTGTTTCCT-3' Newly designed 
Uro-DMF 5'-GGTAGATAGCGGTCCTGGAC-3' Newly designed 
Uro-DM2F 5'-TCCTTCTATCAGTCCAGTCAAGG-3' Newly designed 
Uro-DMR 5'-AACCACCTCATAGCCAGCTT-3' Newly designed 
Uro-DL 5'GGGACAATCTTTCACAAACAAAACTACAC-3' Mendez,M.,Sorkin1998 
pJET 1.2 R 5'-AAGAACATCGATTTTCCATGGCAG-3' Thermo Scientific CloneJET PCR 
Cloning Kit ,#K1231 
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Figure 2.4 : Distribution of primer sets cross UROD gene and the PCR product size. 
 
2.5.1.10 UROD gene and next generation sequencing 
 
For next generation sequencing (NGS), several PCR reactions target regions in the whole 
gene were determined. These regions were amplified by using Long Amp Hot Start TaqX2 
Master Mix (M0533S/Lot:0111503). 
The master mix reaction was done according to the kit leaflet as well as the PCR reaction 
for large sizes of PCR products was started with initial denaturation step for 30 second at 
94ºC. Amplification was achieved in 33 cycles started from denaturation step for 20 
seconds at 94ºC followed by  20 seconds at 55ºC  for annealing and  5 minutes at 65 ºC for 
extension respectively. An additional extension step was performed for a further 10 min at 
65 ºC, to assure a complete extension of the amplified product.  The reaction was then 
cooled down to 4ºC and either stored at -20 ºC or used directly for sequencing. 
For each patient all PCR products were combined then it was purified by using 
AGENCOURT® AMPURE® XP beads (X1) , DNA library was prepared using Nextera 
XT kit (Illumina) according to manufacture protocol. Deep sequencing was done using 
Mid throughput Nextseq kit usigNextSeq500 Illumina machine. 
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2.5.2 UROS gene analysis 
2.5.2.1 RNA Extraction and cDNA production of UROS gene 
 
Previously a novel  mutation T>C was detected in exon 3 of the UROS gene, the substitution of 
serine by proline at the amino acid residue 47 (S47P , rs397515527), hot spot regions within  
exon 10,4, intron and exon 2,all were examined in this study, on the other hand multiple 
alternatively spliced mRNAs were detected earlier, thus mRNA was examined also in this 
study.(Ged et al., 2004a) 
 
Genomic RNA was extracted immediately when the samples were received from buffy coat 
using Nucleospin RNA (DNA, RNA, Protein purified) commercially available kits according to 
the manufactures instructions. Red cell lysis solution was used (EpicentreKit:Master pure DNA 
purification kit for blood version II , Cat.NoMB711740) to get rid from RBCs.The extracted 
RNA (50ng/μL) was converted directly to cDNA using a commercial kit (First Strand cDNA 
Synthesis using ProtoScript II Reverse Transcriptase, M0368). 
 
2.5.2.2Amplification of cDNA – UROS gene and Sanger sequencing 
The amplification process was performed using PCR Q5® High-Fidelity DNA Polymerase kit 
(New England Biolab, M0491).Specific DNA regions were amplified using specific primers that 
were prepared for exons and hotspot areas within UROSgene, F1 primer was excluded since it 
was cross reacted with a genomic DNA sequence and F2 primer was used instead. The PCR 
conditions and gel electrophoresis were followed as mentioned in the kit leaflet. The sequences 
of forward and reverse primers, the annealing temperatures, and the size of PCR product are 
described in the (table 2.3) below. 
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Table 2.3: Newly designed Primers code, sequences and sizes for each target for UROS gene 
Primer code Sequence 5’---3’ PCR product 
Size (bp) 
IntEx2-3 FW 
IntEx2-3 REV 
TCTTTCCGGAACCATAAACG 
CACTGAAGCTGTGGGCACT 
1190 
Ex4 FW 
Ex4  REV 
AAATTCAGTGCCCACAGCTT 
AGAAGTGCAGCTGCTTCTGG 
701 
Ex10 FW 
Ex10 REV 
CAGAAGCTGGGCTAGAATCG 
GTCCTCAGGTGCTTCCACT 
442 
F1-mRNA FW 
F2-mRNA FW 
R-mRNA REV 
ATGGCGGTGCGCATGCGCGA 
ATTGCTCCTGCAGCCTTTT 
AAACCACACTGACTACCTGTGC 
1347(F1R) 
1204(F2R) 
 EX3a FW 
 
EX3a REV 
 
TCAGAGGAACTGACGCAGAA 
 
CCTGGAGCCAGGTGAAGTTA 
 
314 
 
 
2.5.3FECH gene analysis 
After receiving a biochemical results for (24-Hour) urine sample collection for Porphyrins 
fractions analysis, the results were compatible with biochemical characteristics of Erythropoietic 
Protoporphyria (EPP) which oriented us toward screening FECH gene. 
Screening patients for absence of the IVS3-48C allele to select those with the T/T genotype for 
mutational analysis of the FECH gene should identify most patients with autosomal recessive 
disease. 
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Patients and control subjects were genotyped for the FECHIVS3-48C/T polymorphism using a 
set of newly designed primer (GTGTTGTGTGTCCTGAATCTT) and 
(GAATGGTGCCAGCTTACTAAA) to obtain a 282 bp PCR product. 
The amplification process was performed using Thermo scientific X2 PCR master mix kit (Lot: 
00364507) according to the kit instructions.  
The PCR reaction started with initial denaturation step for 2 minutes at 95ºC. Amplification was 
achieved in 35 cycles started from denaturation step for 25 seconds at 95ºC followed by  35 
seconds at 53ºC  for annealing and 40 seconds at 72ºC for extension respectively. An additional 
extension step was performed for a further 5 min at 72 ºC, to assure a complete extension of the 
amplified product. The reaction was then cooled down to 4ºC and either stored at -20 ºC for 
analysis by sequencing and RFLP technique. PCR products was loaded and captured as 
previously described. 
 
2.5.3.1 Restriction fragment length polymorphism for FECHIVS3-48C/T polymorphism 
detection 
The PCR product was digested with TseI restriction enzyme (1 ul) Cat #:R0591S). The digested 
product was loaded on 2% agarose gel and captured as previously mentioned in section 2.4.2.2 
 
2.5.3.2 FECH gene and Next generation sequencing 
After Restriction fragment length polymorphism (RFLP) was performed for FECHIVS3-48C/T 
polymorphism a comprehensive genetic analysis was done for FECH gene by deep sequencing 
in order to detect any probable mutation.  
The steps were followed as mentioned in section 2.4.4.But a slight changing was done for 
smaller size of PCR product by modifying the extension time 1 minute instead of 5 minutes for 
the long sequences as explained in the table below. 
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Table 2.4: Newly designed Primers code, sequences, sizes for each target and the extension time for FECH gene 
Primers code Primers’ sequences Target 
size/bp 
Extension time/ Minutes 
EXON1- PCR1 
 
GGAGCGGGCTTCTAGCTC 
CAGACCCACTTACCGCTCTG 
 
408 1 
EXON2-PCR2 
 
GCCTGCAGAGAAATGCTAGG 
GCTATTGAACGGAAGCCAAG 
 
405 1 
Exon34-PCR3 
Intron3 
TGTGACGGCAGTGAAAAGAG 
AATAGCAGCAGCCTCAATCC 
 
2522 5 
Exon56-PCR4 
Intron 5 
CCGTCAGTGCCATAGGAAAT 
CAAACCCAGAAGGGATGAGA 
 
3900 5 
Exon789- PCR5 
Intron 7,8 
ATGCTGAGAGGCTGGACTGT 
GAGGACACCGTACATGCAAA 
 
5200 
 
5 
Exon10,11-PCR6 
Intron 10 
GGAAGGGGAAGGGACATAAG 
CTGTCCCTGGAGACCAGAAG 
 
1650 1 
Exon 1 –PCR2 AGTCCAGCAGGTTTTGCAGT 
ACCTTCCCTCGCGTAAT 
710 1 
 
Pool of the same sample of PCR 1-6 was collected, purification and library preparation was done 
as mentioned above. DNA sequencing was done as described above on Nextseq 500 machine 
from Illumina. 
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2.6 Bioinformatics analysis 
PCR amplicons were examined by direct automated bidirectional sequencing using the same set 
of primers used for PCR amplification, the results were analyzed using bioinformatics tools: 
Bioedit Program was  used for sequence quality determination: 
http://www.mbio.ncsu.edu/Bioedit/bioedit.html 
NCBI website was used for DNA sequence blast analysis: http://www.ncbi.nlm.nih.gov , and for 
the multiple alignments and homology predication multiple sequence alignment by Florence 
Corpet program was also used http://multalin.toulouse.inra.fr/multalin. For NGS analysis free 
online galaxy program was used: https://usegalaxy.org/ and DNA sequences assembly using 
Geneious bioinformatics software. 
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Chapter 3 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
 Results 
3.1 Patients and Controls 
The history of the targeted families have been started since 65 years ago, symptomatic patients 
were noticed after few months of birth when the child start crawling and becomes exposed to the 
sunlight. 
The Patients age ranges from several months to 65 years, all patients were related to three 
families with a high percentage of consanguineous marriage. Some of them showing a sever 
photosensitivity accompanied by scarring and mutilation. Males and females are likewise 
affected. Photos for some patients are shown in appendix D explaining the symptoms. 
Primarly after the family Pedigrees followed the mode of inhiritance considered as recessive 
inhiritance pattern.The parents appeared normal without any symptoms but one or more siblings 
were affected. Different patients from different families have been chosen for genetic screening 
according to the age group and  severity of symptoms (figure 3.1). 
 
 
Figure 3.1: Family history and the progression of disease  
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3.2 Biochemical Test result 
Table 3.1: The porphyrin and porphyrin precursor levels in urine/24 hrs. Urine collection for 
fourteen patients from three different families 
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1 TMZ 9 F 3.7 2.1 5.0 0.16 3.5 7.3 22.0 
2 TAZ 14 M 7.9 7.4 8.0 1.50 12.5 0.7 37.8 
3 TMYZ 46 F 6.2 0.5 4.0 1.0 2.0 0.9 14.1 
4 TNJK 26 F 4.5 1.7 7.0 2.0 0.4 2.2 17.2 
5 TYK 7 M 2.7 4.7 4.0 0.10 6.0 1.2 19.1 
6 TIZ 15 M 6.4 1.3 1.0 0.097 0.1 0.4 9.4 
7 TST 10 M 5.2 5.1 7.0 0.52 0.4 2.1 20.1 
8 TMT 10 M 2.2 3.1 4.0 0.16 0.2 2.3 11.6 
9 TNET 25 F 4.0 2.8 4.0 0.15 0.3 0.2 12.0 
10 TRK 16 F 26.6 1.8 5.0 0.05 0.8 0.3 35.1 
11 TIK 21 M 4.6 2.1 3.0 0.36 3.6 7.9 21.6 
12 TOK 22 M 2.7 0.7 8.0 0.24 16.7 0.8 29.5 
13 TKHZ 5 M 6.3 5.4 5.0 0.2 8.2 16.2 41.8 
14 TNT 16 F 5.3 2.7 5.0 0.53 0.2 0.05 15.1 
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Biochemical testing involves checking the total porphyrin and porphyrin precursor levels in 
urine. This method is used to diagnose all types of porphyria as each hase a distinctive pattern of 
raised levels. As we noticed from the table above all the values in the range without any 
elevation in any precursor, accordingly this result leaded us to screen the FECH gene that is 
responsible about Erythropoietic Protoporphyria (EPP) symptoms. 
3.3 DNA molecular analysis 
3.3.1UROD molecular DNA Analysis: 
3.3.1.1Cloning UROD gene in a plasmid vector 
  The Clone JET PCR Cloning Kit features the novel positive selection cloning vector 
pJET1.2/blunt. This vector contains a lethal gene which is disrupted by ligation of a DNA 
insert into the cloning site. As a result, only cells with recombinant plasmids are able to 
propagate.  
 
Table 3.2: cloning selection results for three patients  
Patients’ 
Code 
Clones Result 
LT Clone1 
-ve 
Clone2 
-ve 
Clone3  
-ve 
Clone4 
+ve 
Clone5 
+ve 
Clone6 
-ve 
Clone7 
-ve 
Clone8 
+ve 
KZ Clone1 +ve Clone2 +ve Clone3 –ve 
LKH Clone1 –ve Clone2 +ve Clone3 –ve 
 
 
 
 
 
 
 
 
 
Figure 3.2: Detection of positive clones for three patients, the table above demonstrates the results for each clone 
30 
 
 
After extraction of plasmid was done DNA concentrations were in range (57.3 – 100.6) ng/ul, 
aPCR products were loaded in the gel below. But for sequencing separate parts of the gene were 
amplified and prepared for sequencing according to the map in Figure 2.3 
 
 
 
 
 
 
 
 
Figure 3.3: Full UROD gene (3.6 Kb) gene image. From different patients’ Samples,1-3 as shown, Lane 4 negative 
control. lane 5 positive control. 
3.3.1.2 UROD gene sequencing and screening 
Amplification reactions were performed to the UROD gene using different sets of primers as 
mentioned previously. 
The sequencing results were manipulated and the gene asssemply was performed for 3 patients 
KZ, LTand LKH, after assemply completed the total size of the collected fragment was equal to 
the size of the gene 3.6 kb , all single nucleotide polymorphysms existing in the gene were 
documented in specific table for each patient subsecuantly.We started our research by 
investigation the variation in UROD gene because PCT is the most common type of cutaneous 
porphyria around the world. 
The alignment was done by using a RefSeqGene on chromosome1, Homo sapiens 
uroporphyrinogen decarboxylase (UROD), NG_007122.2.  
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Table  3.3: SNPs in UROD Gene for KZ patient 
 
 
 
 
Position 
# 
SNPs Location 
Position 
regarding 
+1 
Clinical 
significant 
rS # Notes 
4846 T>A 5'UTR 263 - N/A 
2236576 
 
Reported 
5503 T>C Intron 1 394   Not reported 
5533 
Hetero C\G 
 
Intron 1 424  
184463721 
for 
(C>T)(N/A) 
Not reported 
 
5604 
C>T 
Comp 
(C>A) 
Intron1 
 
495 N/A 12749939 Reported 
6083 A>G Intron 3 974   
Not reported 
 
6943 
 
G>T Intron6 1835 N/A 11211066 
Reported 
 
6946 A>G Intron6 1838   
Not reported 
 
7045 G>T Intron6 1937 N/A 6698485 
Reported 
 
7219 T>C Intron6 2110   
Not reported 
 
7749 
Com G>A 
A>G 
Intron8 26439   
Not reported 
 
7904 
C>T 
Com(G>A) 
Intron 9 2794 N/A 6429553 
Reported 
 
 
8000 
T>C 
com (A>G) 
Intron 9 2891 N\A 13948 
Reported 
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Table 3.4: SNPs in UROD Gene for LKH patient 
Notes rS # Clinical 
significant 
Position 
regarding 
+1 
Loction SNPs Original 
positin# 
Not reported   -293  5'UTR A>G 4816 
Not reported   -234  5'UTR T>C 4875 
Not reported   365 Intron 1 G>A 
Com(C>T) 
5474 
Reported  
6698485 
 
N/A 1936 Intron6 G>T 
Com(C>A) 
7045 
Not reported   2145 Intron6 A>G 
Com(T>C) 
7254 
Not reported   2650 Intron7 A>G 
Com(T>C) 
7759 
Reported 6429553 
 
N/A 2795 Intron9 C>T 7904 
       
Not reported   2818 Intron9 T>C 7927 
Not reported 
 
  3068 Intron9 delC 8177 
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Table 3.5: SNPs in UROD Gene for LT patient 
 
 
 
Notes rS # Clinical 
significant 
Position 
regardin
g +1 
Position SNPs  Position # 
complement(4846) 
reported   
2236576 
 
N/A 263 - 5'UTR T>A 4846 
Not reported   394 Intron1 T>C 5503 
Not reported   496 Intron1 G>A 5605 
   974 Intron 3 A>G 6083 
Reported 11211066 
 
N/A 1834 Intron6 G>T 6943 
Not Reported   1837 Intron6 A>G 6946 
 6698485 
 
N/A 1936 Intron6 G>T 7045 
Not Reported   2110 Intron6 T>C 7219 
Not reported 
 
   264 Intron8 A>G 7749 
 Reported 6429553 
 
N/A 2795 Intron9 C>T 7904 
Reported 13948 N/A 2891 Intron9 T>C 8000 
Not reported   2818 Intron9 T>C 7927 
Not reported 
 
  3068 Intron9 delC 8177 
34 
 
The variations that were detected in the examined samples for three patients from different 
families have no significant effect even though some of them were reported, continuously we 
went through advanced method (Next Generation sequencing) to detect any mutation that could 
participate in the symptoms. 
 
3.3.1.3 UROD next generation sequencing and screening 
The consenses sequences that were obtained from the Next generation sequencig for UROD  
gene shows some SNPs without any clinical significance as illumenated in the table below, the 
consenses sequences was compared to the reference sequence (Homo sapiens uroporphyrinogen 
decarboxylase,  RefSeqGene on chromosome 1 NCBI Reference Sequence: NG_007122.2). 
Table 3.6: SNPs were detected in UROD by NGS 
SNP # Reference SNP (rs #) RefSNP Alleles Clinical Significance Position Note 
5604 12749939 C/T N/A Intron 1 Khand my 
6943 11211066 G/T N/A Intron6 Khand my 
7045 6698484 G/T N/A Intron 6 Khand my 
7904 6429553 C/T N/A Intron 9 Khand my 
8000 13948 C/T N/A Intron 9 Khand my 
7442 Not Reported T/K -  Intron7 Normal in Kh 
 
3.3.2UROS molecular DNA analysis 
Amplification reactions were performed to the cDNA-UROS and DNA gene in both directions 
using different sets of primers as mentioned previously .The sequencing results were 
manipulated and the gene asssemply was performed . 
We choosed exon 4 ,10 , Intron2, Exon2 and Exon3 regions for amplification and sequencing 
since those targets contain tho most common mutation that cause congenital erythropoietic 
porphyria (CEP) adding to that exon three contains the (S47P) a novel mutation that was 
detected in four siblings of a Palestinian family in France. 
All the sequences were compared with a RefSeqGene on chromosome10, Homo sapiens 
uroporphyrinogen III synthase (UROS), NG_011557.1. All the alignment results for all patients 
from different three families were normal without any significant SNP 
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Figure 3.4: Three hot spot areas of UROS gene were amplified for sequencing, Samples for three unrelated 
patients1-3 as shown, Lane 4 negative control 
Regarding to the cDNA amplification for four unrelated patients and one control, The figure 
below shows that the cDNA for affected patient and normal control unchanged furthermore the 
product size equal the Coding region mRNA (1354 bp) so there is no exon skipping. 
 
 
Figure 3.5: cDNA was amplified for UROS gene for four unrelated patients (Lane1-4) 
Lane5 for a control, lane6 for a negative control (Product size for each target illustrated in table 2.3) 
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3.3.3 FECH molecular DNA analysis 
We explored the most common mutation that cause the autosomal recessive pattern of 
inheritance in EPP(SNP; IVS3-48C/T) allele that  appears to explain the occurrence of 
photosensitivity in most EPP families, so we amplified the region in intron three that contains 
this SNP,as illumenated in the figure below with 282 bp for the target size, but we didn’t find the 
SNP. 
 
Figure 3.6: Intron3 (IVS3-48C/T allele) was amplified from different sample patients 1-5, using specific primers. 
Lane 6 negative control, PCR product 282 bp 
After that the product was restricted by restriction enzyme TSeI, and we got the pands with a 
total sequence size 282bp so allele C present, while allele T the mutant one not present which 
give the following pattern of restriction (29 and 253 bp). 
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Figure 3.7: Restriction fragment length polymorphism (RFLP) analysis after digestion the PCR product by TSeI, 
enzyme. Product was loaded on 3% agarose gel. 1 to 5 represent samples sequence and a total sequence size 282bp 
was obtained , 100 bp ladder was used . 
 
Finally we amplified the FECH gene in separet target as shown in table 2.4, the gel image below 
shows some of  the PCR product that were ready for deep sequencing. 
Figure 3.8: PCR product for FECH gene, ready for Next generation sequencing.( Product size for each 
PCR reaction illustrated in table 2.4). 
 
The consenses sequences that were optained from the Next generation sequencing for two 
unrelated patients shows that FECH gene in the amplified regions was normal without any 
significant variation, the consenses sequences was compared to the reference sequence (Homo 
sapiens ferrochelatase (FECH), RefSeqGene on chromosome 18,NCBI Reference Sequence: 
NG_008175.1). 
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Chapter 4 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
Discussion and conclusions 
4.1 Discussion 
In this study we investigated the molecular basis of cutaneous porphyria with recessive mode of 
inheritance or reduced (incomplete) penetrance that include familial porphyria cutaneous tarda 
(fPCT), Hepatoerythropoietic porphyria (HEP), Congenital erythropoietic porphyria (CEP) and 
erythropoietic protoporphyria (EPP). 
The samples were tested from different patients, families, ages and the severity of the symptoms 
were diverse. 
During this investigation and genetic studies on UROD and UROS genes, a biochemical test  
(24Hours urine collection) was performed in specialist lab in Jordan for fourteen patients, the 
results illuminated in section 3.2 showed that all porphyrin precursors and total porphyrin were 
within the normal range, on the other hands the biochemical results in the normal range without 
increasing in porphyrin or porphyrin precursors oriented us to go through FECH gene screening 
according to the criteria in (table 1.2). 
 
The screening of three unrelated patients for UROD gene was performed by cloning the gene 
followed by PCR and sequencing of full gene using DNA. 
The molecular heterogeneity of type II PCT is demonstrated by different mutations reported in 
the UROD gene, remarkably, in the majority of the reported cases of fPCT, mutations are unique 
in each individual family. 
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In this study we found different variations some of them were reported the others not, one of 
them was in the 5’UTR region which was reported in the Genbank under rs:2236576 without any 
pathogenic effect.  
The substitution of serine by proline at the amino acid residue 47 (S47P) was present at the 
homozygous state in four patients of a Palestinian family in the present study, we investigated   
this mutation in our patients particularly the CEP that caused by a genetic changing in UROS 
gene which was compatible with the mode of inheritance of our patients. However, no mutations 
were detected in all tested sequences. Based on literature review, we summarized the most 
common mutations that can cause CEP and three region in UROS gene were examined without 
any detectable mutation. 
Subsequently the mRNA was examined by converting it to cDNA to confirm the presence of all 
exons without any skipping especially in exon4 and exon10. 
This finding nominated FECH gene for screening because EPP is the only type of cutaneous 
porphyria that gives a normal porphyrin level in a biochemical test and that related to the nature 
of its precursor (Protoporphyrin) which is unlike other porphyrins, is lipophilic molecule and 
thus detached from the body only through hepatic excretion into bile or feces, accordingly in 
contrast to the other forms of cutaneous porphyria the urinary porphyrins are usually normal. 
The FECH gene screening was started to identify the most common mutation that was reported 
widely and cause the autosomal recessive pattern of inheritance in EPP (SNP; IVS3-48C/T) 
allele that appears to explain the occurrence of photosensitivity in most EPP families, but the 
sequencing results showed a normal sequence in the tested patients. 
 
To screen the FECH and UROD genes deeply we used Next generetion sequencing technology 
and the multiple alignment of a consences sequenses of two patients with the reference sequence 
of the genes  gave a normal result and no significant mutation was detected. 
 
This final result complicated the interpretation of the results and leaded us to perform further 
investigation to make  matching between the biochemical and genetic results adding to that there 
are variations with regard to diagnostic stratigies and clinical intrpretation even between these 
specialized labooratories and diagnostic centers. 
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4.2.Conclusions and Recommendations 
Porphyria is not a single disease but a group of at least eight disorders. The diagnosis of   
porphyria can be difficult. As a group, these diseases are rare, and the signs and symptoms of the 
disease may mimic other more common diseases. Adding to that, this is the first time where such 
a study is performed in Palestine to diagnose those patients, so there are no baseline 
investigations, and moreover there is a lack of porphyria investigation in the Arab population 
was also observed. 
So the screening of a mutation in at least three genes the smallest one around 3600 bp is a huge 
job and requires a lot of resources and tests with different molecular techniques. 
 
Respectively we have to focus on many facts about this disease regarding the regulation of the 
genes encoding the eight enzymes of heme biosynthesis pathway that can occur at 
transcriptional, translational and post translational levels adding to that the relationship between 
different genes like Human hemochromatosis protein (HFE) gene.  
In addition, further studies need to confirm our mutations finding in vitro, such as in vitro 
expression testing of normal and mutant genes in tissue culture cells including GFP or luciferase 
expression reporters.  
Mutations in the HFE gene that cause hereditary hemochromatosis increase the risk of 
developing the most common form of porphyria, Porphyria Cutanea Tarda. So it is 
recommended to investigate the mutations in HFE gene to confirm or exclude this relationship. 
 
Also when the biochemical test for erythrocytes becomes available it is recommended to test the 
patients’ blood porphyrin especially for EPP confirmation or exclusion in a definite manner. 
Also in porphyria, there is a lot of intervening sequences mutation that affect the gene or the 
enzyme activity, so it will be helpful to investigate the areas that not covered in our study and to 
do prokaryotic expression studies. 
Finally it’s highly recommended to follow up the patients and provide them with a proper 
treatment that can reduce the photosensitivity symptoms. 
In conclusion, deeper molecular tests are needed such as  exome/whole genome sequencing  and 
epigentic modification analysis for all genes that involved in heme synthesis pathway. However, 
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new genetic disorder with symptoms similar to that of cutaneous porphyria should be considered 
and investigated to complete our work and achieve the main objectives. 
 
4.3 Limitations 
 
We faced many limitations during the sample collection, because the patients were disappointed 
related to the negative feedback from the previous researchers. 
On the other hand the financial issues delayed the biochemical test so many genetic studies were 
performed before receiving the biochemical results. 
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Appendix A : Patients’ Photos shows a mild to severe symptoms 
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 في مىطقة الخليل، فلسطيهبورفيريبالتشخيص الجسيئي للمرضى المشتبه ببصببتهم بمرض ال
 
 : وورش زيذان حسه فبتووي اعذاد الطبلبة
 : د. زيبد عببذيهالمشرف 
 خص المل
اٌجٛسفٍشٌبد ً٘ اضطشاثبد غٍش ِزدبٔسخ رٕدُ ػٓ رشٛ٘بد فً اٌخطٛاد اٌىٍٍّبئٍخ اٌزً رؤدي إٌى إٔزبج اٌٍُٙ،  
زٍث ٌؼزجش ِٓ اُ٘  اٌدضٌئبد اٌسٌٍٛخ اٌضشٚسٌخ ٌدٍّغ أخٙضح اٌدسُ ٚٚظبئفٗ اٌسٌٍٛخ. رٕشأ أػشاض اٌجٛسفٍشٌب فً 
ٌدٍذ.  ٕ٘بن أٛاع ِزؼذدح ٌٍّشض رظٙش ثصٛس ػذح ٌٚىٓ الأٛاع اٌغبٌت ِٓ آثبس لذ رزشوض ػٍى  اٌدٙبص اٌؼصجً أٚ ا
). غبٌجب ِب ٌزأخش اٌزشخٍص اٌصسٍر لأْ PPE dna PEC ,PEH ,TCPfاٌزً رصبزجٙب اػشاض خٍذٌخ ً٘ (
الأػشاض غٍش ِسذدح. ٌّىٓ أْ رشًّ اٌّظب٘ش اٌدٍذٌخ زشق، ٚأزفبخبد ٚرٕذة خبصخ فً  إٌّبطك اٌّؼشضخ 
 لأشؼخ اٌشّس.
اَْ ٌُ ٌىٓ ٕ٘بن أي رمشٌش اٚ دساسخ ػٓ اٌزسًٍٍ اٌدضٌئً اٌدًٍٕ ٌٍجٛسفٍشٌب فً اٌّشضى اٌفٍسطٍٍٍٕٓ. ٚوبْ  ززى
اٌٙذف ِٓ ٘زٖ اٌذساسخ ٘ٛ رأوٍذ اٌزشخٍص اٌسشٌشي ٌٍجٛسفٍشٌب ِٓ خلاي اخزجبساد اٌىٍٍّبء اٌسٌٍٛخ ٚاٌذساسبد 
 ٌّشزجٗ ثُٙ ٚرسذٌذ اٌدٍٓ اٌزي ٌسجت اٌزٛصٍف اٌّظٙشي ٚالأػشاض فً ِٕطمخ اٌخًٍٍ.اٌٛساثٍخ ٌٍّشضى ا
ٚسٍشبسن اٌزشخٍص اٌّؤوذ ٚساثٍب فً اٌسذ ِٓ اَثبس اٌفظٍؼخ ٌٍّشض، ٚسٍسُٙ ثشىً وجٍش فً صسخ اٌّشضى 
ص اٌصسٍر ٚاٌّجىش اٌفٍسطٍٍٍٕٓ ٚزبلاد اٌطفشح غٍش اٌّزدبٔسخ سشٌشٌب غٍش اٌّزٕبظشح داخً الأسش، ٚسٍّىٓ اٌزشخٍ
ِٕبست اٌّشىٍخ ٚاٌزمًٍٍ ِٓ ػذد اٌّٛاٌٍذ اٌدذد اٌّصبثٍٓ ، ٚرٛخٍٗ اٌّصبثٍٓ ٌّٕظ زٍبح  لإداسحِٓ ٚضغ خطخ 
 اطفبي ِصبثٍٓ. لإٔدبةاٌّؼشضخ  ٌلأسش، ٚرمذٌُ اٌّشٛسح اٌدٍٍٕخ الأفضً ٌٍزخفٍف ِٓ الاػشاض ٚشذرٙب
فً ٘زٖ اٌذساسخ، ٚأخشٌذ اٌذساسبد اٌٛساثٍخ ٚاٌجٍٛوٍٍّبئٍخ  اٌخًٍٍ -ِشٌضب رمشٌجب  ِٓ ِذٌٕخ رفٛذ 04ٚلذ شبسن 
 .ٚاٌىشف ػٓ اٌطفشاد اٌّسججخ ٌٍّشضثبسزخذاَ رمٍٕبد خضٌئٍخ ِخزٍفخ ٌٍزشخٍص 
، ِّب ٌمٛدٔب اٌى اٌّضٌذ ِٓ اٌجسث ِٓ دْٚ اثش رشخٍصً ػٍى اٌّشضى ٌطفشادٌٕزبئح ٚخٛد ػذد ِٓ اٚاظٙشد ا
ػٕذ اٌّشضى اٚ اٌزٛخٗ ٌٍىشف  اٌّٛخٛدحِؤثشاد خٍٍٕخ لذ رسجت الاػشاض خلاي طشق اوثش رمذِب ػٓ طفشاد اٚ 
ٚرٌه اسزىّبلا ٌّب لّٕب ثٗ ِٓ اخً رسمٍك وبفخ الا٘ذاف  خذٌذا ػٓ طفشاد رزؼٍك ثّشض اخش سٛاء وبْ ِؼشٚفب اٚ
 اٌّشخٛح .
 
